Concourse Financial Group Securities, Inc. Neu Base Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$0.17 - $0.39 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023
BUY
$0.18 - $0.3 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$0.41 - $1.3 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$0.82 - $1.93 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$1.26 - $2.95 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$2.6 - $4.18 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$3.27 - $4.76 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$4.63 - $7.34 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$6.92 - $12.36 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$6.92 - $9.25 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
BUY
$7.25 - $9.71 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020
BUY
$6.69 - $11.51 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020
BUY
$4.77 - $8.23 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020
BUY
$4.5 - $8.1 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019
BUY
$3.15 - $6.59 $0 - $0
0 New
0 $0

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email